| 2.735 0.275 (11.18%) | 10-15 14:27 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 3.17 |
1-year : | 3.7 |
| Resists | First : | 2.71 |
Second : | 3.17 |
| Pivot price | 2.31 |
|||
| Supports | First : | 2.21 |
Second : | 1.89 |
| MAs | MA(5) : | 2.46 |
MA(20) : | 2.26 |
| MA(100) : | 2.12 |
MA(250) : | 2.3  |
|
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 77.2 |
D(3) : | 74.1 |
| RSI | RSI(14): 64.2 |
|||
| 52-week | High : | 4.61 | Low : | 1.07 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ PRQR ] has closed It is unclear right now based on current values. 57.5% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 0 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 2.49 - 2.5 | 2.5 - 2.52 |
| Low: | 2.17 - 2.19 | 2.19 - 2.2 |
| Close: | 2.44 - 2.46 | 2.46 - 2.48 |
ProQR Therapeutics N.V., a biopharmaceutical company, engages in the discovery and development of RNA-based therapeutics for the treatment of genetic disorders. It primarily develops sepofarsen that is in phase II/III clinical trial illuminate trial for treating leber congenital amaurosis 10 disease; and ultevursen, which is in phase II/III clinical trial to treat USH2A-mediated retinitis pigmentosa and usher syndrome. The company also engages in the developing of Axiomer RNA base-editing platform technology. It has a license agreement with Radboud University Medical Center, Inserm Transfert SA, Ionis Pharmaceuticals, Inc., and Leiden University Medical Center, as well as license and research collaboration with Eli Lilly and Company for the discovery, development, and commercialization of potential new medicines for genetic disorders in the liver and nervous system. ProQR Therapeutics N.V. was incorporated in 2012 and is headquartered in Leiden, the Netherlands.
Wed, 15 Oct 2025
ProQR stock rating reiterated at Market Outperform by Citizens - Investing.com
Mon, 13 Oct 2025
ProQR Therapeutics to Participate in Upcoming Investor Conferences with Focus on RNA Editing Technology - Quiver Quantitative
Mon, 13 Oct 2025
Oct 14–22, 2025: ProQR to Present at Three Investor Conferences; RNA Editing Panel Oct 21, webcasts available - Stock Titan
Mon, 13 Oct 2025
ProQR to Participate in Upcoming Investor Conferences in October 2025 - Yahoo
Fri, 10 Oct 2025
ProQR Therapeutics' (PRQR) Sell (D-) Rating Reiterated at Weiss Ratings - MarketBeat
Fri, 10 Oct 2025
ProQR Therapeutics N.V.'s (NASDAQ:PRQR) Price Is Out Of Tune With Revenues - simplywall.st
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 105 (M) |
| Shares Float | 65 (M) |
| Held by Insiders | 18 (%) |
| Held by Institutions | 52.6 (%) |
| Shares Short | 1,160 (K) |
| Shares Short P.Month | 550 (K) |
| EPS | -0.47 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.63 |
| Profit Margin | -231.5 % |
| Operating Margin | -308.2 % |
| Return on Assets (ttm) | -20.5 % |
| Return on Equity (ttm) | -79.5 % |
| Qtrly Rev. Growth | -38.5 % |
| Gross Profit (p.s.) | 0.16 |
| Sales Per Share | 0.16 |
| EBITDA (p.s.) | -0.39 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -42 (M) |
| Levered Free Cash Flow | -25 (M) |
| PE Ratio | -5.64 |
| PEG Ratio | 0 |
| Price to Book value | 4.14 |
| Price to Sales | 16.28 |
| Price to Cash Flow | -6.62 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|